{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T12:34:51Z","timestamp":1773923691292,"version":"3.50.1"},"reference-count":26,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T00:00:00Z","timestamp":1367452800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J of Urology"],"published-print":{"date-parts":[[2013,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Botulinum toxin <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content> is available under three different protein complexes that are not interchangeable until appropriate comparative studies are undertaken. The best studied for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity and overactive bladder\/idiopathic detrusor overactivity is onabotulinum toxin <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content>. This brand is only approved for the treatment of urinary incontinence as a result of neurogenic detrusor overactivity at a dose of 200\u2009<jats:styled-content style=\"fixed-case\">U<\/jats:styled-content> and idiopathic detrusor overactivity at a dose of 100\u2009<jats:styled-content style=\"fixed-case\">U<\/jats:styled-content>. In patients with detrusor overactivity as a result of spinal cord injury or multiple sclerosis, 200\u2009U of onabotulinum toxin <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content> should be injected in 30 different sites above the trigone. It was shown to be highly effective in curing or decreasing urinary symptoms of incontinence, increasing quality of life, increasing bladder capacity and decreasing maximal detrusor pressure. This effect was independent of the concomitant use of oral anticholinergic drugs. Adverse events were mild, mainly urinary tract infections and high postvoid residual requiring clean intermittent catheterization. In patients with overactive bladder\/idiopathic detrusor overactivity, 100\u2009<jats:styled-content style=\"fixed-case\">U<\/jats:styled-content> of onabotulinum toxin <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content> should be injected in 20 sites above the trigone. It markedly decreases urinary incontinence and improves quality of life. Frequency and urgency episodes are also decreased. Adverse events are mild, mainly urinary tract infections and urinary retention. The latter occurred in just 5% of the patients. Candidates for onabotulinum toxin <jats:styled-content style=\"fixed-case\">A<\/jats:styled-content> treatment should be warned that the effect of the toxin is transient and that repeated injections will be required to maintain the effect in the long term. There is no evidence that repeated injections will have a decreased efficacy.<\/jats:p>","DOI":"10.1111\/iju.12188","type":"journal-article","created":{"date-parts":[[2013,5,2]],"date-time":"2013-05-02T14:13:53Z","timestamp":1367504033000},"page":"956-962","source":"Crossref","is-referenced-by-count":20,"title":["Botulinum toxin treatment for bladder dysfunction"],"prefix":"10.1111","volume":"20","author":[{"given":"Andr\u00e9","family":"Santos\u2010Silva","sequence":"first","affiliation":[{"name":"Department of Urology Faculty of Medicine and Hospital de S\u00e3o Jo\u00e3o  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlos Martins","family":"da Silva","sequence":"additional","affiliation":[{"name":"Department of Urology Faculty of Medicine and Hospital de S\u00e3o Jo\u00e3o  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco","family":"Cruz","sequence":"additional","affiliation":[{"name":"Department of Urology Faculty of Medicine and Hospital de S\u00e3o Jo\u00e3o  Porto Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,5,2]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.002"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.01.125"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)67283-7"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000162035.73977.1c"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.07.001"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.05.035"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2010.08.021"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2008.03.028"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2009.01.117"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.01.130"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.056"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.028"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.12.022"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1208872"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.10.043"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2011.12.011"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000143189.19835.f3"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(05)00322-8"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000127725.48479.89"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.002"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.10.032"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2009.08495.x"},{"key":"e_1_2_10_24_1","first-page":"197","article-title":"Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome","volume":"15","author":"Chung SD","year":"2012","journal-title":"Pain Physician"},{"key":"e_1_2_10_25_1","first-page":"E15","article-title":"Repeated onabotulinumtoxin\u2010a injections provide better results than single injection in treatment of painful bladder syndrome","volume":"16","author":"Kuo HC","year":"2013","journal-title":"Pain Physician"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.02.031"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2012.09.027"}],"container-title":["International Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fiju.12188","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/iju.12188","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T17:30:34Z","timestamp":1696354234000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/iju.12188"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,2]]},"references-count":26,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["10.1111\/iju.12188"],"URL":"https:\/\/doi.org\/10.1111\/iju.12188","archive":["Portico"],"relation":{},"ISSN":["0919-8172","1442-2042"],"issn-type":[{"value":"0919-8172","type":"print"},{"value":"1442-2042","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,2]]}}}